Balversa
Term · Oncology and biomedicine · MLC-T-ONC-000906
A drug used to treat adults with urothelial cancer (a type of bladder or urinary tract cancer) that has spread and has an abnormal FGFR3 gene. It is used in patients whose cancer got worse during or after treatment with at least one type of systemic therapy. It is also being studied in the treatment of other types of cancer. Balversa blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called erdafitinib.
| Identifier | MLC-T-ONC-000906 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | erdafitinib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-000906",
"term": "Balversa",
"field": "Oncology and biomedicine",
"definition": "A drug used to treat adults with urothelial cancer (a type of bladder or urinary tract cancer) that has spread and has an abnormal FGFR3 gene. It is used in patients whose cancer got worse during or after treatment with at least one type of systemic therapy. It is also being studied in the treatment of other types of cancer. Balversa blocks a protein called FGFR, which may help keep cancer cells from growing and may kill them. It is a type of tyrosine kinase inhibitor. Also called erdafitinib.",
"synonyms": [
"erdafitinib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/balversa/"
}
Record 3,270 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.